Akebia Therapeutics Ownership | Who Owns Akebia Therapeutics?

Overview Forecast RevenueFinancials Chart Transcripts

Akebia Therapeutics Ownership Summary

Akebia Therapeutics is owned by 45.98% institutional investors, 3.56% insiders, and 50.46% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 7.80% of AKBA shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.96% of its assets in Akebia Therapeutics shares.

AKBA Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Akebia Therapeutics	45.98%	3.56%	50.46%
Sector	Healthcare Stocks	488.30%	11.08%	-399.38%
Industry	Biotech Stocks	307.10%	11.11%	-218.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock funding, inc. /de	18.37M	7.80%	$66.88M
Blackrock	11.64M	5.68%	$11.87M
Vanguard group	10.88M	5.17%	$20.68M
State street	6.30M	3.00%	$11.98M
Alerce investment management	5.75M	2.73%	$10.92M
Geode capital management	4.80M	2.28%	$9.11M
Renaissance	3.82M	1.82%	$7.26M
Bioimpact capital	2.89M	1.23%	$10.52M
Jacobs levy equity management	2.09M	1.02%	$2.14M
Nantahala capital management	2.00M	0.85%	$7.28M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Alerce investment management	5.75M	19.23%	$10.92M
Great point partners	1.99M	4.70%	$7.23M
Bioimpact capital	2.89M	1.82%	$10.52M
Affinity asset advisors	1.95M	0.97%	$7.10M
Nantahala capital management	2.00M	0.29%	$7.28M
Orchard capital management	53.51K	0.22%	$194.78K
Diametric capital, lp	57.53K	0.11%	$209.42K
Entrypoint capital	41.00K	0.07%	$149.22K
Wealth effects	34.50K	0.05%	$125.58K
Alphamark advisors	38.46K	0.03%	$73.00K

Top Buyers

Holder	Shares	% Assets	Change
Blackrock	11.64M	0.00%	9.10M
Blackrock funding, inc. /de	18.37M	0.00%	3.04M
Bioimpact capital	2.89M	1.82%	2.89M
State street	6.30M	0.00%	2.87M
Acadian asset management	1.35M	0.01%	1.35M

Top Sellers

Holder	Shares	% Assets	Change
Great point partners	1.99M	4.70%	-2.99M
Aigh capital management	-	-	-2.92M
Monashee investment management	-	-	-1.50M
Balyasny asset management	9.15K	0.00%	-1.24M
Axa	-	-	-627.89K

New Positions

Holder	Shares	% Assets	Change	Value
Bioimpact capital	2.89M	1.82%	2.89M	$10.52M
Acadian asset management	1.35M	0.01%	1.35M	$4.91M
Assenagon asset management	426.77K	0.00%	426.77K	$1.17M
Exoduspoint capital management, lp	289.53K	0.01%	289.53K	$1.05M
Walleye capital	214.82K	0.00%	214.82K	$781.93K

Sold Out

Holder	Change
Northwestern mutual wealth management	-5.00
Stephens consulting	-6.00
Capital performance advisors llp	-68.00
Hexagon capital partners	-186.00
Laurel wealth advisors	-229.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2025	162	8.72%	108,281,334	13.45%	45	2.80%	111	19.35%	23	-11.54%
Mar 31, 2025	150	19.05%	95,500,610	40.77%	40	3.90%	94	34.29%	27	22.73%
Dec 31, 2024	124	4.20%	67,787,367	14.05%	32	4.04%	70	18.64%	22	-15.38%
Sep 30, 2024	118	9.26%	59,390,703	5.52%	28	3.74%	59	9.26%	26	8.33%
Jun 30, 2024	108	-14.29%	56,234,084	-1.41%	27	3.04%	53	-27.40%	24	-

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	7.79M	2.96%	-172.84K
Vanguard US Total Market Shares ETF	5.95M	2.52%	-
iShares Russell 2000 ETF	6.06M	2.29%	-
SPDR® S&P Biotech ETF	3.09M	1.17%	6.91K
Vanguard Institutional Extnd Mkt Idx Tr	2.59M	0.99%	-1.16M
Fidelity Small Cap Index	2.50M	0.94%	312.83K
Foord Global Equity (Lux) A	1.99M	0.76%	1.99M
iShares Russell 2000 Value ETF	1.96M	0.74%	-
Foord Global Equity Class B	1.83M	0.70%	1.83M
Nuveen Quant Small Cap Equity R6	1.79M	0.68%	-276.70K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jun 30, 2025	Ostrowski Erik	SVP, CFO, CBO & Treasurer	Sell	$151.62K
Jun 09, 2025	Malabre Richard C	SVP, Chief Accounting Officer	Sell	$60.15K
Jun 04, 2025	Malabre Richard C	SVP, Chief Accounting Officer	Sell	$47.07K
Mar 03, 2025	Butler John P.	CEO and President	Sell	$84.93K
Mar 03, 2025	Burke Steven Keith	SVP, Chief Medical Officer	Sell	$13.07K

Insider Transactions Trends

Date	Buy	Sell
2025 Q2	-	3
2025 Q1	-	8
2024 Q2	-	2
2024 Q1	-	10
2023 Q3	-	1

AKBA Ownership FAQ

Who Owns Akebia Therapeutics?

Akebia Therapeutics shareholders are primarily institutional investors at 45.98%, followed by 3.56% insiders and 50.46% retail investors. The average institutional ownership in Akebia Therapeutics's industry, Biotech Stocks , is 307.10%, which Akebia Therapeutics falls below.

Who owns the most shares of Akebia Therapeutics?

Akebia Therapeutics’s largest shareholders are Blackrock funding, inc. /de (18.37M shares, 7.80%), Blackrock (11.64M shares, 5.68%), and Vanguard group (10.88M shares, 5.17%). Together, they hold 18.66% of Akebia Therapeutics’s total shares outstanding.

Does Blackrock own Akebia Therapeutics?

Yes, BlackRock owns 5.68% of Akebia Therapeutics, totaling 11.64M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 11.87M$. In the last quarter, BlackRock increased its holdings by 9.1M shares, a 358.35% change.

Who is Akebia Therapeutics’s biggest shareholder by percentage of total assets invested?

Alerce investment management is Akebia Therapeutics’s biggest shareholder by percentage of total assets invested, with 19.23% of its assets in 5.75M Akebia Therapeutics shares, valued at 10.92M$.

Who is the top mutual fund holder of Akebia Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Akebia Therapeutics shares, with 2.96% of its total shares outstanding invested in 7.79M Akebia Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools